Merus ( ($MRUS) ) has provided an update. On September 29, 2025, Merus N.V. entered into a transaction agreement under which Genmab A/S, through ...

Merus’ NRG1 gene targeting cancer treatment helped to shrink tumors and kept working for up to 9.1 months, leaving the company’s leadership with an important question: partner up or go it alone for ...

Biologist Eduard Batlle used to spend his weekends at his parents’ confectionery. Now he’s one of the six inventors of ...

If you want to know who really controls Merus N.V. (NASDAQ:MRUS), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, institutions will increase their ...

Shares of Merus fell 6% Monday morning as an interim update for a bispecific therapy revealed three deaths in the lung cancer portion of an ongoing trial. MCLA-129 is being assessed in 60 patients ...

Merus N.V. (NASDAQ:MRUS) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab ...

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration ...

Merus has announced a research collaboration and license agreement with Biohaven. Under the agreement, Biohaven and Merus will to co-develop three antibody-based therapies. Market-moving news hits ...

On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung ...

However, even though Dragon Ball Super has now seemingly taken Merus off of the game board, the character’s introduction seems too significant to be a simple one-off. Given everything we’ve learned ...